Overview

Patents & Intellectual Property (IP)

ACT owns or licenses more than 150 patents and patent applications related to stem cell therapy and regenerative medicine. ACT recently secured a patent on its “embryo-safe” single-blastomere technology and in June of 2010 secured a broad patent for production of RPE cells.

Stock Listing

OTC-BB: ACTC
Quote: 0.0899
Change: -0.0029
Date: “2/4/2014″
Time: 2:49:15 AM
Yahoo Finance